GLPG Galapagos NV

Galapagos to present at upcoming investor conferences

Galapagos to present at upcoming investor conferences

Mechelen, Belgium; 24 August 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that management will participate in the following upcoming investor conferences: 

  • Citi’s 17th Annual Biopharma Conference. September 8, 2022 in Boston
  • Morgan Stanley 20th Global Healthcare Conference. September 12-14, 2022 in New York
  • Bank of America Merrill Lynch Global Healthcare Conference. September 15, 2022 in London
  • KBC Securities Virtual Life Sciences Conference. September 16, 2022
  • JP Morgan CEO Call Series. September 28, 2022
  • Credit Suisse 31st Annual Healthcare Conference. November 8-10, 2022 in Rancho Palos Verdes, CA
  • Bryan Garnier Virtual Conference on Cell Therapy Innovation. November 14, 2022
  • Jefferies 2022 Global Healthcare Conference. November 16-17, 2022 in London
  • Kepler Cheuvreux Virtual Life Science Days. November 21, 2022
  • Deutsche Bank 2022 Call Series. November 30, 2022



Additional information regarding these events will be available on the investor section of the Galapagos website at .

About Galapagos

Galapagos is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 3 programs in inflammation, oncology, fibrosis, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is approved and available in the European Union (including Norway), Great Britain and Japan. For additional information, please visit or follow us on or .

Contact

Investors:

Sofie Van Gijsel

Head of Investor Relations

Sandra Cauwenberghs

Director Investor Relations

3

Media:

Marieke Vermeersch

Head of Corporate Communication



Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

 

Attachment



EN
24/08/2022

Underlying

GLPGGalapagos NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Galapagos NV

Jacob Mekhael
  • Jacob Mekhael
GLPG GALAPAGOS NV
AUTL Autolus Therape... ... (+3)

EHA abstracts Autolus, Galapagos, MaaT

The abstracts for presentations at EHA (12-15 June) became available yesterday during the day (here). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (long-term findings and predictors of sustained remission for Aucatzyl in r/r adult ALL, as well as age stratified outcomes), Galapagos (more data and follow up from its decentralised CAR-T program) and MaaT (additional data from ...

GLPG GALAPAGOS NV
AUTL AUTOLUS THERAPEUTICS ADS
MAAT MAAT PHARMA SA
05/15/25 May 15, 2025 1 EN
 PRESS RELEASE
Free
GLPG GALAPAGOS NV

Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring ...

Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101 Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that new data from our ongoing ATALANTA-1 Phase 1/2 study of GLPG5101 in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) have been accepted for oral presentations at the 2025 European Hematology Association (EHA) Congre...

May 14, 2025 1 EN
 PRESS RELEASE
Free
GLPG GALAPAGOS NV

Galapagos kondigt mondelinge presentaties aan tijdens EHA en ICML 2025...

Galapagos kondigt mondelinge presentaties aan tijdens EHA en ICML 2025 met veelbelovende nieuwe resultaten uit de ATALANTA-1 studie met CAR-T kandidaat GLPG5101 Mechelen, België; 14 mei 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), een wereldwijd biotechnologiebedrijf dat zich toelegt op het veranderen van de resultaten voor patiënten door middel van levensveranderende wetenschap en innovatie, kondigde vandaag aan dat nieuwe gegevens uit haar lopende ATALANTA-1 fase 1/2-studie met GLPG5101 bij patiënten met recidief/refractair non-Hodgkin lymfoom (R/R NHL) geaccepteerd zijn voor ...

May 14, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
GLPG GALAPAGOS NV

Galapagos 1-1 mgmt. call feedback on re-evaluation of company split

We had a 1-1 call with Galapagos' mgmt. including Henry Gosebruch, newly appointed CEO, and Jérôme Contamine, newly appointed chairman of the board following this morning's announcement regarding the re-evaluation of the proposed company split in favour of strategic alternatives for the cell therapy business. Our takeaway is this new approach leads to a similar outcome intended with the split, but through a smoother path. We summarise our key takeaways in this note.

05/13/25 May 13, 2025 1 EN
Jacob Mekhael ... (+5)
  • Jacob Mekhael
  • Kristof Samoy
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
ENX EURONEXT NV
SOLB SOLVAY SA ... (+7)

Morning Notes : ENX FP, GLPG NA, HYL BB, SOLB BB, TWEKA NA, EKOP BB, A...

: ENX FP, GLPG NA, HYL BB, SOLB BB, TWEKA NA, EKOP BB, ALFEN NA

ENX EURONEXT NV
SOLB SOLVAY SA
TWEKA TKH GROUP N.V. CERT
GLPG GALAPAGOS NV
ALFEN ALFEN NV
HYL HYLORIS PHARMACEUTICALS
EKOP EKOPAK NV
05/13/25 May 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch